AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05676528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
Study NCT05723055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
Study NCT05723055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
Study NCT05313633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Both groups received a designed occupational therapy program for 30 minutes
Study NCT05313633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association.
Study NCT05313633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii training
Description: The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device.
Study NCT05520996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberball
Description: Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
Study NCT05528042 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heart rate and respiratory rate measurement
Description: Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting
Study NCT06306612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Chemohormonal Therapy
Description: Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
Study NCT06306612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemohormonal Therapy
Description: Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
Study NCT06306612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Hormonal Therapy
Description: Under continuous ADT, oral darolutamide 600mg twice per day
Study NCT06306612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Hormonal Therapy
Description: Under continuous ADT, oral darolutamide 600mg twice per day
Study NCT06306612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Prostatectomy
Description: Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.
Study NCT06306612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Adjuvant Radiotherapy
Description: Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
Study NCT05070403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40 MG
Description: Participants will receive 40 mg Afatinib, once daily.
Study NCT05055128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.
Study NCT05055128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Dummy
Description: Patients will receive matching placebo capsules for Lansoprazole.
Study NCT05693155 — intervention group
Intervention type: BEHAVIORAL
Intervention: Voluntary self-exclusion from gambling ('Spelpaus')
Description: Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
Study NCT05395481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3849891
Description: Administered SC.
Study NCT06266312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A multimodal prehabilitation programme
Description: 1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. + strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week.
Study NCT05395481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT06475170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: proximal gastrectomy combined with 'λ+α' double-tract anastomosis
Description: 1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；
Study NCT06475170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal gastrectomy combined with 'λ+α' double-tract anastomosis
Description: 1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；
Study NCT01048151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFerade™ Biologic
Description: AdGVEGR.TNF.11D
Study NCT05426291 — intervention group
Intervention type: OTHER
Intervention: BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?
Description: In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
Study NCT04980222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
Study NCT05660863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-08 24 mg/day
Description: Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
Study NCT05660863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-08 60 mg/day
Description: Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
Study NCT06148779 — intervention group
Intervention type: BEHAVIORAL
Intervention: Digitally delivered first-line treatment for osteoarthritis
Description: Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.
Study NCT06148779 — intervention group
Intervention type: BEHAVIORAL
Intervention: Face-to-face first-line treatment for osteoarthritis
Description: First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
Study NCT04411823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP measurement
Description: EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
Study NCT06105801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial ultrasound with transbronchial needle aspiration
Description: Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
Study NCT06105801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound with transbronchial needle aspiration
Description: Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
Study NCT06105801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Participants will undergo Bronchoscopy
Study NCT06105801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Participants will undergo Bronchoscopy
Study NCT06105801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Participants will undergo Cryobiopsy
Study NCT06427369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radioconjugate
Description: 1241-hJAA-F11 IV administration
Study NCT06427369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: PET/CT Imaging
Study NCT06427369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: PET/CT Imaging
Study NCT06427369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography and Computed Tomography Scan
Description: FDG PET/CT Imaging
Study NCT06427369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Blood sample collection imaging
Study NCT06638398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo standard of care Computed Tomography
Study NCT06638398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo standard of care Computed Tomography
Study NCT06638398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Procedure
Description: Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.
Study NCT06638398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care lung nodule management
Study NCT06638398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care lung nodule management
Study NCT06638398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary Studies
Study NCT04822883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RL-007
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Study NCT04822883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RL-007 Matching Placebo
Description: Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
Study NCT06244823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab Prefilled Syringe
Description: MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
Study NCT06282393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FibriCheck recordings
Description: PPG and single-lead ECG measurements
Study NCT06238271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acriva BB UDM 611
Description: Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
Study NCT05103917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: CXCR4 inhibitor
Study NCT04906876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as a 90-minute IV infusion
Study NCT05702203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Music Therapy
Description: Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
Study NCT04496674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1 and Toczilizumab
Description: Adminsitration of CC-1 and Toczilizumab
Study NCT05478902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Exercise protocol for rotator cuff related shoulder pain
Study NCT05478902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: High Energy Extracorporeal Shockwave Therapy
Study NCT05478902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Percutaneous Irrigation
Description: Two sessions of Ultrasound-Guided Percutaneous Irrigation
Study NCT06048341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06048341 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06048341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Study NCT06048341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study NCT04301674 — intervention group
Intervention type: DEVICE
Intervention: Breath Biopsy
Description: ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
Study NCT05717985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified combined approach
Description: A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
Study NCT05717985 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: de-epithelized gingival graft
Description: Only dressing material will be placed at the donor site after graft harvesting
Study NCT06226974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: * Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation.
Study NCT06158854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383 (Etentamig)
Description: Intravenous Infusion
Study NCT05972239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pulmonary rehabilitation program
Description: Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
Study NCT05972239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training added on standard pulmonary rehabilitation
Description: Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
Study NCT06492031 — intervention group
Intervention type: DRUG
Intervention: Icodextrin Peritoneal Dialysis Solution
Description: The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.